Income Statement Presentation 2023

2022: Portfolio diversification accelerating Currently 16 blockbusters, with Vabysmo and Phesgo emerging Ocrevus Hemlibra Vabysmo Evrysdi Tecentriq Phesgo Ronapreve Polivy Alecensa Perjeta Xolair Kadcyla Enspryng n/a 87% 14% 121% 85% 15% 5% 9% 7% 93% >500% 17% 27% 17% Xofluza Gazyva Tamiflu Esbriet Lucentis -31% -28% Herceptin -19% MabThera -20% Actemra/RoActemra -22% 9% 80% US ■ Europe Japan International Avastin -28% T -1,200 -800 -400 400 800 Absolute values and growth rates at Constant Exchange Rates (CER) 1,200 Roche 22 22

View entire presentation